KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EPS (Weighted Average and Diluted) (2016 - 2025)

Sarepta Therapeutics has reported EPS (Weighted Average and Diluted) over the past 11 years, most recently at -$3.93 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$3.93 for Q4 2025, down 362.0% from a year ago — trailing twelve months through Dec 2025 was -$7.14 (down 413.16% YoY), and the annual figure for FY2025 was -$7.13, down 404.7%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$3.93 at Sarepta Therapeutics, down from -$0.5 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for SRPT hit a ceiling of $1.89 in Q2 2025 and a floor of -$4.6 in Q1 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.5 (2025), compared with a mean of -$0.87.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 2600.0% in 2025, while the deepest fall reached 1343.24% in 2025.
  • Sarepta Therapeutics' EPS (Weighted Average and Diluted) stood at -$1.43 in 2021, then rose by 13.29% to -$1.24 in 2022, then skyrocketed by 161.29% to $0.76 in 2023, then surged by 97.37% to $1.5 in 2024, then crashed by 362.0% to -$3.93 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$3.93 (Q4 2025), -$0.5 (Q3 2025), and $1.89 (Q2 2025) per Business Quant data.